Mar. 19 at 4:00 PM
$TPST currently testing a critical floor at its 52-week low of
$2.12, showing tight consolidation as the market weighs a massive valuation gap against near-term funding needs. While the stock has seen a slow bleed, the narrative is shifting toward its newly acquired CAR-T (TPST-2003) portfolio, which recently posted a stellar 100% response rate in early multiple myeloma data and secured a key manufacturing deal on March 11. With amezalpat (1120) officially Phase 3-ready and backed by FDA Fast Track status, the make or break moment arrives with the upcoming earnings call (expected March 26–30). Investors are laser-focused on management’s ability to prove a cash runway through mid-2027 without heavy dilution; if they succeed, the distance between the current
$2.21 price and H.C. Wainwright’s
$11.00 price target could start to close rapidly.
